SNOA Key Statistics, Chart & Performance
The current stock price of SNOA is 3.65 USD. In the past month the price decreased by -2.8%. In the past year, price increased by 40.38%.
SNOA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.37 | 1.01T | ||
| JNJ | JOHNSON & JOHNSON | 19.69 | 492.44B | ||
| MRK | MERCK & CO. INC. | 12.55 | 274.34B | ||
| PFE | PFIZER INC | 7.96 | 144.87B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.52 | 113.72B | ||
| ZTS | ZOETIS INC | 20.06 | 56.04B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.77 | 23.19B | ||
| VTRS | VIATRIS INC | 5.48 | 14.70B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.45 | 11.66B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.54B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.53B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 5.05B |
Related stock screener links
About SNOA
Company Profile
Sonoma Pharmaceuticals, Inc. is a global healthcare leader in the development and production of stabilized hypochlorous acid (HOCl) products. The company is headquartered in Boulder, Colorado and currently employs 168 full-time employees. The company went IPO on 2007-01-26. The firm is engaged in developing and producing stabilized hypochlorous acid (HOCl) products for a range of applications, including wound care, eye care, nasal care, oral care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Its products are all classified as medical devices and categorized as prescription, over-the-counter (OTC) and office dispense products. The company offers both prescription and OTC dermatology products, including Epicyn Facial Cleanser, Levicyn Dermal Spray, Levicyn Gel, Levicyn Spray Gel, Celacyn Scar Management Gel. In the United States, it offers Microcyn wound and skin care both as an OTC and prescription product. Its eyecare products include Acuiycn Eyelid and Eyelash Hygiene, and Ocucyn Eyelid and Eyelash Cleanser. MicrocynAH is an HOCl-based topical product that cleans, debrides and treats a wide spectrum of animal wounds and infections.
Company Info
SONOMA PHARMACEUTICALS INC
5445 Conestoga Court, Suite 150
Boulder COLORADO 30189 US
CEO: Amy Trombly
Employees: 168
Phone: 18007599305
SONOMA PHARMACEUTICALS INC / SNOA FAQ
What does SONOMA PHARMACEUTICALS INC do?
Sonoma Pharmaceuticals, Inc. is a global healthcare leader in the development and production of stabilized hypochlorous acid (HOCl) products. The company is headquartered in Boulder, Colorado and currently employs 168 full-time employees. The company went IPO on 2007-01-26. The firm is engaged in developing and producing stabilized hypochlorous acid (HOCl) products for a range of applications, including wound care, eye care, nasal care, oral care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Its products are all classified as medical devices and categorized as prescription, over-the-counter (OTC) and office dispense products. The company offers both prescription and OTC dermatology products, including Epicyn Facial Cleanser, Levicyn Dermal Spray, Levicyn Gel, Levicyn Spray Gel, Celacyn Scar Management Gel. In the United States, it offers Microcyn wound and skin care both as an OTC and prescription product. Its eyecare products include Acuiycn Eyelid and Eyelash Hygiene, and Ocucyn Eyelid and Eyelash Cleanser. MicrocynAH is an HOCl-based topical product that cleans, debrides and treats a wide spectrum of animal wounds and infections.
Can you provide the latest stock price for SONOMA PHARMACEUTICALS INC?
The current stock price of SNOA is 3.65 USD. The price decreased by -3.44% in the last trading session.
What is the dividend status of SONOMA PHARMACEUTICALS INC?
SNOA does not pay a dividend.
What is the ChartMill rating of SONOMA PHARMACEUTICALS INC stock?
SNOA has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What sector and industry does SONOMA PHARMACEUTICALS INC belong to?
SONOMA PHARMACEUTICALS INC (SNOA) operates in the Health Care sector and the Pharmaceuticals industry.
Is SONOMA PHARMACEUTICALS INC (SNOA) expected to grow?
The Revenue of SONOMA PHARMACEUTICALS INC (SNOA) is expected to grow by 11.38% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the number of employees for SONOMA PHARMACEUTICALS INC?
SONOMA PHARMACEUTICALS INC (SNOA) currently has 168 employees.
SNOA Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to SNOA. When comparing the yearly performance of all stocks, SNOA is one of the better performing stocks in the market, outperforming 73.21% of all stocks.
SNOA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SNOA. The financial health of SNOA is average, but there are quite some concerns on its profitability.
SNOA Financial Highlights
Over the last trailing twelve months SNOA reported a non-GAAP Earnings per Share(EPS) of -2.2. The EPS increased by 55.3% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -25.11% | ||
| ROE | -91.87% | ||
| Debt/Equity | 0.01 |
SNOA Forecast & Estimates
7 analysts have analysed SNOA and the average price target is 15.1 USD. This implies a price increase of 313.59% is expected in the next year compared to the current price of 3.65.
For the next year, analysts expect an EPS growth of -96.42% and a revenue growth 11.38% for SNOA